Clinical trials: Infections, Staphylococcal
Atopic Dermatitis, Staphylococcus Aureus
Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Clinical studies have demonstrated a link between staphylococcal skin colonization and the pathogenesis of AD, but the implication of bacterial…
- Conditions
- Atopic Dermatitis, Staphylococcus Aureus, Bacterial Toxins, Immune Response
- Trial name
- STADEH (NCT04274348)
- Testing
- Skin biopsies and blood samples
- Where
- 2 sites in France
- Volunteers
- 41 people
- Sponsor
- Poitiers University Hospital
Neonatal Staphylococcal Sepsis
Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110
"Phase I/II, Randomized, Double Blind, Placebo Controlled, Dose Escalating, Safety and Pharmacokinetics Study in Very Low Birth Weight Neonates of Four Doses of BSYX-A110 for the Prevention of S.
- Trial name
- N002 (NCT00631878)
- Testing
- Pagibaximab (formerly BSYX-A110)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Biosynexus Incorporated
Healthy
Inflammation, Intracellular Invasion and Colonization of the Nasal Mucosa by Staphylococcus Aureus
An inflammatory state of the nasal cells (very close to keratinocytes) could favour the internalization of Staphylococcus aureus and thus constitute a persistent reservoir for the carriage of this bacterium.
- Trial name
- I3COSa (NCT04469348)
- Testing
- nasal swab
- Where
- France
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Autosomal-dominant Hyper-IgE Syndrome
Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
Background: AD-HIES is a disease that weakens the immune system. It puts people at risk for infections, particularly Staph and Candida infections.
- Trial name
- NCT02996448
- Testing
- NDV-3A
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Impetigo, Folliculitis
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections…
- Conditions
- Impetigo, Folliculitis, Secondarily Infected Eczema, Minor Soft Tissue Infections
- Trial name
- NCT01126268
- Testing
- Retapamulin (Altabax)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- The University of Texas Health Science Center, Houston
Prosthetic-joint Infection, Infection Hip
Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection
In this Dutch multicenter clinical trial, patients with a staphylococcal prosthetic joint infection, will, in the oral antibiotic treatment phase, be randomized between clindamycin monotherapy and rifampicin / levofloxacin…
- Conditions
- Prosthetic-joint Infection, Infection Hip, Infection; Knee, Joint
- Trial name
- RiCOTTA (NCT06172010)
- Testing
- Clindamycin, Rifampicin and levofloxacin
- Where
- 13 sites in Netherlands
- Volunteers
- 316 people
- Sponsor
- Leiden University Medical Center
Soft Tissue Infections, Necrotizing Fasciitis
Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
This proposal focuses on highly lethal destructive tissue infections, i.e. necrotizing fasciitis and other necrotizing soft tissue infections (NSTIs), which are associated with high morbidity and mortality.
- Conditions
- Soft Tissue Infections, Necrotizing Fasciitis, Necrotizing Soft Tissue Infections
- Trial name
- INFECT (NCT01790698)
- Where
- 5 sites in Denmark, Norway and 1 more
- Volunteers
- 409 people
- Sponsor
- Karolinska Institutet
Staphylococcus Aureus
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body.
- Trial name
- NCT01011335
- Testing
- Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT
- Where
- 2 sites in United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Staphylococcal Infections
Preoperative Nasal Swabs From Pediatric Patients
We intend to take a nasal swab from each pediatric pre-operative patient in our out-clinic with the intention of looking for a connection between positive operative incisions and a positive nasal swab.
- Trial name
- NCT00646919
- Testing
- Nose swab
- Where
- Israel
- Sponsor
- Hillel Yaffe Medical Center
Drug Resistance, Microbial
Quinolone Resistance Profiles and Mechanisms of Staphylococcus Aureus and Escherichia Coli From Humans, Chicken and Catfish Farms in Indonesia
The goal of this observational study is to reveal quinolone resistance profiles and mechanisms in S. aureus and E. coli in the human, animal and aquaculture sector in Blitar, Indonesia.
- Trial name
- QUINDO (NCT05652556)
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Cystic Fibrosis
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
- Trial name
- STAR-TER (NCT03489629)
- Testing
- Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of North Carolina, Chapel Hill
Staphylococcus Aureus Bacteremia
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
This study is a Phase I/II, double-blind, placebo-controlled trial investigating the True Human monoclonal antibody 514G3 in subjects hospitalized with Staphylococcus aureus bacteremia.
- Trial name
- NCT02357966
- Testing
- 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- XBiotech, Inc.
Staphylococcal Infections
Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients' Clinical Outcome in Orthopedic Device Related Bone Infections
This was a prospective study performed between November 2011 and September 2013. Patients with a confirmed S. aureus infection after fracture fixation or prosthetic joint infection were included.
- Trial name
- StaphType (NCT02971657)
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- BG Unfallklinik Murnau
Bacterial Resistance, Infection Resistant to Multiple Drugs
SATURN 04 Nosocomial Acquisition Study
The study is the WP4 of the EU-funded (7th FW) project SATURN (Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria). A total of 6 surgical and 6 medical wards will participate in the study.
- Conditions
- Bacterial Resistance, Infection Resistant to Multiple Drugs, Staph Aureus Methicillin Resistant Colonization, Infection Due to ESBL Bacteria
- Trial name
- SATURN (NCT01208519)
- Where
- 3 sites in Italy, Romania and 1 more
- Volunteers
- 16,680 people
- Sponsor
- Catholic University of the Sacred Heart
Staphylococcal Infections
Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus
Patients admitted into the Intensive Care Unit (ICU) have an intravenous (IV) catheter (small plastic tube) placed in their vein.
- Trial name
- NCT00175370
- Testing
- Vancomycin
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Staphylococcal Infections
Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections
This was a prospective study performed between November 2011 and September 2013. Patients with a confirmed S. epidermidis infection after fracture fixation or prosthetic joint infection were included.
- Trial name
- NCT02640937
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- BG Unfallklinik Murnau
Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus
Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia
"Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia remains a major cause of community- or hospital-acquired bloodstream infections with an overall mortality estimated around 25%.
- Trial name
- CLOCEBA (NCT03248063)
- Testing
- Cloxacillin, Cefazolin
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Surgical Site Infection, Staphylococcus Aureus Infection
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S.
- Conditions
- Surgical Site Infection, Staphylococcus Aureus Infection, Pseudomonas Aeruginosa Infection, Bacterial Infections
- Trial name
- NCT06319235
- Testing
- IMP
- Where
- Czechia
- Volunteers
- 52 people
- Sponsor
- MB PHARMA s.r.o.
Carbuncle
Comparison of Wound Healing for Diabetic Carbuncle Treated With Incision and Drainage Technique Using Cruciate Incision vs Saucerization Technique Both Followed by Vacuum Assisted Closure.
The goal of this clinical trial is to compare the effectiveness of two surgical techniques for wound healing in diabetic patients aged 25-70 years with a carbuncle requiring surgical drainage.
- Trial name
- NCT07428265
- Testing
- Incision & Drainage Technique Using Cruciate Incision Followed by VAC, Saucerization Technique Followed by VAC
- Where
- Pakistan
- Volunteers
- 124 people
- Sponsor
- King Edward Medical University
Staphylococcal Infections
V710 First-In-Man (FIM) Study (V710-001)
This is a randomized, Multicenter, double-blind (subject, investigator, and Merck Research Laboratories (MRL) clinical personnel directly involved in the study), placebo-controlled, dose-ranging study in healthy adults 18 to 55…
- Trial name
- NCT00303069
- Testing
- V710
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC